New migraine drug ubrogepant tested in canadian Real-World study
NCT ID NCT06692881
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study looks at how well the migraine drug ubrogepant works in everyday life for Canadian adults. About 178 participants will take the drug as prescribed and report their ability to function normally after a migraine attack. The goal is to see if ubrogepant helps people get back to daily activities quickly and if they are satisfied with the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ubrogepant
What this could lead to
If successful, this study could confirm that ubrogepant helps people with migraine return to normal activities quickly after an attack.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows people for 12 weeks, so long-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
360 Concussion Care /ID# 271972
Ottawa, Ontario, K1H 7X7, Canada
-
Bayshore Neurology /ID# 280213
Ottawa, Ontario, K2B 8E8, Canada
-
Burrard Health Center /ID# 271474
Vancouver, British Columbia, V6Z 2E8, Canada
-
Calgary Headache Assessment and Management Program /ID# 271475
Calgary, Alberta, T3M 1M4, Canada
-
Centre de Recherche St-Louis /ID# 272843
Lévis, Quebec, G6W 0M5, Canada
-
Centricity /ID# 271477
London, Ontario, N6A 2C2, Canada
-
Diex Recherche Sherbrooke /ID# 271677
Sherbrooke, Quebec, J1L 0H8, Canada
-
Genge Partners /ID# 273302
Montreal, Quebec, H4A 3T2, Canada
-
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 272031
London, Ontario, N6A 5W9, Canada
-
Maritime Neurology /ID# 271867
Halifax, Nova Scotia, B3R 1V9, Canada
-
Neurocentre of Eastern Ontario /ID# 271865
Kingston, Ontario, K7M 8H9, Canada
-
Royal Jubilee Hospital /ID# 271476
Victoria, British Columbia, V8R 1J8, Canada
-
Sunnybrook Health Sciences Centre /ID# 276844
Toronto, Ontario, M4N 3M5, Canada